CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,328 enrolled
Drug / intervention
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine +2 morebiological
Likely dose
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04143061
NCT04143061Phase 3Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

Sanofi Pasteur, a Sanofi Company·interventional·Posted Oct 29, 2019·Updated Feb 3, 2025

In Brief

A Phase 3 clinical trial evaluating Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, and 1 other intervention for Meningococcal Immunization and Healthy Volunteers. Completed, enrolled 1,328 participants across 17 sites in 2 countries.

Detailed Summary

This will be a Phase III, modified double-blind (open-label for toddlers in India), randomized, parallel-group, active-controlled, step-wise, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adults, adolescents, children, and toddlers in India and a modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adolescents and children in RSA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia, South Africa
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedOct 29, 2019
Enrollment StartDec 30, 2019
Primary CompletionJan 28, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.7 years ago

Interventions

Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccinebiological

Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL

Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccinebiological

Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL

Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccinebiological

Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL